isturisa osilodrostat Cushings
Selected indexed studies
- Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. (J Clin Endocrinol Metab, 2022) [PMID:35325149]
- Osilodrostat: First Approval. (Drugs, 2020) [PMID:32141023]
- Osilodrostat (Isturisa) for Cushing's disease. (Med Lett Drugs Ther, 2021) [PMID:33647005]
_Worker-drafted node — pending editorial review._
Connections
isturisa osilodrostat Cushings is a side effect of
Sources
- Osilodrostat (Isturisa) for Cushing's disease. (2021) pubmed
- New Trends in Treating Cushing's Disease. (2024) pubmed
- Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. (2022) pubmed
- Osilodrostat: Short Chapter. (2012) pubmed
- Osilodrostat: First Approval. (2020) pubmed
- Osilodrostat for Cushing Disease and Its Role in Pediatrics. (2023) pubmed
- Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France. (2023) pubmed
- Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. (2020) pubmed
- Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome. (2025) pubmed
- Osilodrostat Treatment of Cushing Syndrome in Real-World Clinical Practice: Findings From the ILLUSTRATE study. (2025) pubmed